Table 1

Effectiveness of anti-TNF therapies in treatment of Crohn's disease in three separate studies

Treatment GroupInfliximab 5 mg/kgEtanercept 25 mg s.c.CDP571 10 mg/kg
Placebo1-a 4/24 (17%)9/20 (45%)15/56 (27%)
Anti-TNF treatment1-a 1-b 22/27 (81%)9/23 (39%)29/54 (54%)
No. to treat1.6N/A3.7
Odds ratio (confidence interval)20.8
(4.95, 87.4)
0.78
(0.23, 2.63)
3.17
(1.43, 7.03)
  • N/A, not applicable.

  • 1-a  Number of patients that showed a 70-point decrease in their Crohn's disease activity index/number of patients treated.

  • 1-b  Most efficacious dose evaluated in study.